Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Merrell Dow

Executive Summary

Collaboration with Mitsubishi Kasei covers the North American development and marketing of pharmaceutical products discovered by the Japanese company. Under the agreement announced April 8, the two firms will review Mitsubishi Kasei compounds that are currently in clinical development in Japan, as well as compounds that enter clinical trials in the next seven years. Some of the products to be covered under the agreement are already in Phase II trials in Japan, though none have begun clinical trials in the U.S.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel